Active Biotech AB Provides Update on the Scheduled Clinical Program for 2024
approval process are advancing according to plan. As communicated earlier, Active Biotech will focus its project pipeline on the development of tasquinimod in myelofibrosis, a blood cancer with high medical need, and the company plans to start clinical phase II proof-of-concept studies in Europe and in the US in 2024. The start of the European study within the HOVON network, with full external funding by Oncode, which previously was planned to start in the latter part of First Quarter 2024, will not start until Third Quarter 2024, due to administrative procedures of these multicenter trials in Germany and the Netherlands. It is a monotherapy study of tasquinimod in patients ineligible to receive JAK inhibitor treatment, with Professor Rebekka Schneider-Kramann as its Lead Principal Investigator. In parallel, a clinical phase II study in myelofibrosis in the US is prepared in collaboration with the University of Texas MD Anderson Cancer Center. This study will evaluate tasquinimod alone and in combination with the JAK inhibitor ruxolitinib. It is currently undergoing internal review at MD Anderson prior to regulatory submission. The review procedure is advancing ahead of plan, and it currently see a possible start of the study already in mid-2024.